Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 vs taxane in previously treated HER2-positive advanced gastric cancer
jRCT2080221881Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab emtansine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Gastric cancer (HER2-positive) and 1 more (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
trastuzumab emtansine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaGastric cancer (HER2-positive)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080221881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221881.